WO2012050975A3 - Nouvelles molécules d'arn circulaire de mammifère et utilisations associées - Google Patents
Nouvelles molécules d'arn circulaire de mammifère et utilisations associées Download PDFInfo
- Publication number
- WO2012050975A3 WO2012050975A3 PCT/US2011/054004 US2011054004W WO2012050975A3 WO 2012050975 A3 WO2012050975 A3 WO 2012050975A3 US 2011054004 W US2011054004 W US 2011054004W WO 2012050975 A3 WO2012050975 A3 WO 2012050975A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rna molecules
- mammalian rna
- novel circular
- methods
- anril
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention concerne des acides nucléiques isolés et purifiés codant pour un ARN circulaire comprenant un ou plusieurs exons ANRIL, des procédés de détection de ces acides nucléiques, et leurs utilisations. L'invention concerne des procédés de détection de troubles associés à ANRIL tels que l'athérosclérose, des kits associés, et des procédés de criblage de composés destinés à prévenir ou traiter ces troubles.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38791810P | 2010-09-29 | 2010-09-29 | |
US61/387,918 | 2010-09-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012050975A2 WO2012050975A2 (fr) | 2012-04-19 |
WO2012050975A3 true WO2012050975A3 (fr) | 2012-07-05 |
Family
ID=45938895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/054004 WO2012050975A2 (fr) | 2010-09-29 | 2011-09-29 | Nouvelles molécules d'arn circulaire de mammifère et utilisations associées |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012050975A2 (fr) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3578205A1 (fr) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | Compositions pharmaceutiques a base d'acides nucléiques modifiés et leur utilisation medicale |
AU2011308496A1 (en) | 2010-10-01 | 2013-05-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
HRP20220717T1 (hr) | 2011-12-16 | 2022-07-22 | Modernatx, Inc. | Modificirani pripravci mrna |
EP2834358A4 (fr) | 2012-04-02 | 2016-03-09 | Moderna Therapeutics Inc | Polynucléotides modifiés destinés à la production de protéines nucléaires |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
EP4074834A1 (fr) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Arn à terminaison modifiée |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP3041938A1 (fr) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Polynucléotides circulaires |
EP3052106A4 (fr) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucléotides codant des polypeptides de modulation immunitaire |
EP3052521A1 (fr) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucléotides codant pour un récepteur de lipoprotéines de faible densité |
EP3054017A1 (fr) * | 2015-02-03 | 2016-08-10 | Johann Wolfgang Goethe-Universität, Frankfurt am Main | ARN circulaire pour le diagnostic et traitement de maladies cardiovasculaires |
WO2016130943A1 (fr) | 2015-02-13 | 2016-08-18 | Rana Therapeutics, Inc. | Oligonucléotides hybrides et leurs utilisations |
US10760131B2 (en) | 2015-02-24 | 2020-09-01 | The Adminstrators Of The Tulane Educational Fund | Methods of detecting, diagnosing, and treating atherosclerotic plaque rupture |
CN106047989A (zh) * | 2015-04-08 | 2016-10-26 | 中国科学院北京基因组研究所 | 一种环状rna在结直肠癌检验标志物中的应用 |
CN106148494A (zh) * | 2015-04-08 | 2016-11-23 | 中国科学院北京基因组研究所 | 一种环状rna在结直肠癌生物标志物中的应用 |
CN106148495A (zh) * | 2015-04-08 | 2016-11-23 | 中国科学院北京基因组研究所 | 一种环状rna在结直肠癌生物标志物中的应用 |
CN105039337B (zh) * | 2015-08-31 | 2017-08-15 | 安徽农业大学 | 5′RACE RNA接头序列及用于扩增miRNA剪切后的靶基因cDNA 5′末端的试剂盒 |
LU92830B1 (en) * | 2015-09-15 | 2017-04-03 | Luxembourg Inst Of Health Lih | Biomarkers for heart failure |
ES2774519T3 (es) * | 2015-09-29 | 2020-07-21 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Un método para diagnosticar una enfermedad mediante la detección de ARNcirc en fluidos corporales |
CN105803101A (zh) * | 2016-05-20 | 2016-07-27 | 上海伯豪生物技术有限公司 | 检测环状rna表达丰度的探针、基因芯片及方法 |
CN106222174B (zh) * | 2016-08-12 | 2020-08-04 | 青岛大学 | circRNA CHIF核苷酸在治疗心脏疾病中的用途 |
CN106138081B (zh) * | 2016-08-12 | 2018-06-22 | 青岛大学 | 一种靶向circRNA的药物组合物及其用途 |
CN106222173B (zh) * | 2016-08-12 | 2020-09-18 | 青岛大学附属医院 | circRNA MNCR在调节心肌细胞坏死和心肌缺血损伤中的作用 |
CN109504750A (zh) * | 2017-07-14 | 2019-03-22 | 戴勇 | Plc围手术期肝移植患者环状rna差异性表达谱图谱模型及其构建方法和构建系统 |
CN107557474B (zh) * | 2017-10-27 | 2020-05-08 | 中南大学湘雅医院 | 胶质瘤诊断标志物circ15:98707562|98708107及应用 |
CN108624589B (zh) * | 2018-04-17 | 2021-12-17 | 广州永诺生物科技有限公司 | 环状RNA circ-ERBB2及其检测试剂与应用 |
CN108611418A (zh) * | 2018-05-10 | 2018-10-02 | 山东大学第二医院 | 一种检测非小细胞肺癌的特异性表达图谱及检测分析系统 |
CN108796086B (zh) * | 2018-07-04 | 2021-07-30 | 聊城市人民医院 | 一种环状RNAcircBCBM1及其非诊断性荧光定量检测方法 |
CN109439747B (zh) * | 2018-09-17 | 2021-07-30 | 昆明医科大学第一附属医院 | 一组用于肺癌诊断的circRNA标志物及其应用 |
CN109136377B (zh) * | 2018-09-25 | 2021-09-28 | 浙江师范大学 | 成人t细胞白血病的治疗药物及诊断试剂盒 |
CN109295221B (zh) * | 2018-10-08 | 2021-07-27 | 暨南大学 | 环状rna作为结直肠癌分子标志物的应用 |
CN109280705A (zh) * | 2018-12-11 | 2019-01-29 | 宁夏医科大学总医院 | 一种环状RNA hsa-circ-0044506及其特异性扩增引物和应用 |
CN109371025A (zh) * | 2018-12-11 | 2019-02-22 | 宁夏医科大学总医院 | 一种环状RNA hsa-circ-0044508及其特异性扩增引物和应用 |
CN110923321B (zh) * | 2019-12-26 | 2022-08-02 | 广东省人民医院(广东省医学科学院) | 一种环状rna检测试剂盒预测三阴性乳腺癌新辅助化疗反应性 |
CN113549679A (zh) * | 2021-07-08 | 2021-10-26 | 南京市儿童医院 | LncRNA ANRIL在儿童急性淋巴细胞白血病中的临床应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2218784A1 (fr) * | 2009-02-04 | 2010-08-18 | Universität Leipzig | Vecteur(s) contenant un gène inductible codant un inhibiteur CDK4/CD6 utile pour traiter les troubles neuro-dégénératifs |
-
2011
- 2011-09-29 WO PCT/US2011/054004 patent/WO2012050975A2/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2218784A1 (fr) * | 2009-02-04 | 2010-08-18 | Universität Leipzig | Vecteur(s) contenant un gène inductible codant un inhibiteur CDK4/CD6 utile pour traiter les troubles neuro-dégénératifs |
Non-Patent Citations (3)
Title |
---|
CHRISTIN E. BURD ET AL.: "Expression of Linear and Novel Circular Forms of an INK4/ARF-Associated Non-Coding RNA Correlates with Atherosclerosis Risk", PLOS GENETICS, vol. 6, no. 12, E1, 2 December 2010 (2010-12-02), pages 1 - 5 * |
ERIC PASMANT ET AL.: "Characterization of a Germ-Line Deletion, Including the Entire INK4/ARF Locus, in a Melanoma-Neural System Tumor Family: Identification of ANRIL, an Antisense Noncoding RNA Whose Expression Coclusters with ARF", CANCER RESEARCH, vol. 67, no. 8, 17 April 2007 (2007-04-17), pages 3963 - 3969 * |
YAN LIU ET AL.: "INK4/ARF Transcript Expression Is Associated with Chromosome 9p21 Variants Linked to Atherosclerosis", PLOS ONE, vol. 4, no. 4, E50, 3 April 2009 (2009-04-03), pages 1 - 5 * |
Also Published As
Publication number | Publication date |
---|---|
WO2012050975A2 (fr) | 2012-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012050975A3 (fr) | Nouvelles molécules d'arn circulaire de mammifère et utilisations associées | |
PL2089343T3 (pl) | Reakcja chemiczna typu click do wytwarzania cząsteczek reporterowych | |
WO2011079902A3 (fr) | Matériaux biologiques et utilisations de ceux-ci | |
GB201020995D0 (en) | Biological materials and uses thereof | |
WO2009151691A3 (fr) | Polymorphismes génétiques associés à une thrombose veineuse, leurs procédés de détection et leurs utilisations | |
WO2009111676A3 (fr) | Petites molécules contenant du bore utilisées en tant qu'agents anti-inflammatoires | |
WO2014028429A3 (fr) | Enzymes et polymérases destinées à la synthèse d'arn | |
WO2012034116A3 (fr) | Petites molécules à titre de modulateurs épigénétiques de la déméthylase 1 spécifique de la lysine et méthodes de traitement de troubles | |
WO2008151170A3 (fr) | Procédé de synthèse du rameltéon et ses intermédiaires | |
WO2013085850A3 (fr) | Synthèse stéréosélective totale de la noribogaïne | |
WO2011077099A3 (fr) | Procédés de purification de cucurbiturile | |
WO2010059317A3 (fr) | Procédé de séparation | |
WO2012083969A3 (fr) | Microarn pour le diagnostic du cancer du pancréas | |
WO2011160052A3 (fr) | Procédés et compositions associés à des arn-endonucléases spécifiques d'une séquence | |
WO2012061502A3 (fr) | Polymorphismes génétiques associés à la thrombose veineuse et la réponse à la statine, procédés de détection et utilisations de ceux-ci | |
WO2014018601A3 (fr) | Nouveaux domaines de liaison d'acide nucléique spécifiques à la base modulaires à partir de protéines burkholderia rhizoxinica | |
WO2008066869A3 (fr) | Systèmes et procédés de suivi de l'amplification et du comportement en matière de dissociation de molécules d'adn | |
WO2011091435A3 (fr) | Méthodes de traitement de maladies hépatiques | |
WO2012017329A3 (fr) | Procédé destiné à des événements génomiques ciblés dans des algues | |
WO2013028334A3 (fr) | Utilisation de petites molécules dans des procédés de purification de biomolécules | |
WO2012136898A3 (fr) | Nouvelles cutinases, leur préparation et leurs utilisations | |
WO2012062753A9 (fr) | Procédé et dispositif pour l'isolement et la purification d'acides nucléiques double brin | |
WO2011130426A3 (fr) | Compositions et procédés de traitement de mélanome | |
WO2010148191A3 (fr) | Compositions et procédés pour des cyclofructanes en tant qu'agents de séparation | |
WO2011021177A3 (fr) | Compositions et procédés de pronostic et de traitement du cancer de la prostate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11833115 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11833115 Country of ref document: EP Kind code of ref document: A2 |